The DEVOTE Programme launched earlier this month (April 2023 ), with three innovative projects which individually represent a collaboration between clinicians, academia, and industry partners, in support of the development of technology which addresses a clear unmet 'need' for patient care and healthcare professionals.
DEVOTE aims to advance technologies being developed across a translational pathway, from biomarker to point of care.
In the North West, the programme links with PROGRESS, about identifying how pharmacogenetics can be used to improve patient outcomes when they need treatment with common medicines like anti-depressants and statins.
Significant funding has been secured by The University of Manchester, which builds on the successful PALOH study where Professor Bill Newman and colleagues, showed that point-of-care genetic testing could be used in neonatal units to prevent babies from losing their hearing.